Latest News

Category: News

See all

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

ASX, Clinical, News,

Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.   ASCO GU, the leading specialised event for GU cancer care worldwide, will be...

Read more

Telix Announces Executive Leadership Appointments

ASX, News,

Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession...

Read more

Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand

News,

Telix today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an...

Read more

First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy

ASX, Clinical, News,

Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent...

Read more

Presentation to Jefferies London Healthcare Conference

Events, News,

Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies London Healthcare Conference in London on Thursday 17 November...

Read more

Telix Acquires Optimal Tracers

ASX, News,

Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development...

Read more

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

ASX, Clinical, News,

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...

Read more

EANM 2022 wrap-up : Shifting perspectives in genitourinary oncology through nuclear medicine

Events, News,

At our recent EANM 2022 symposium, Telix brought together some of the world’s key opinion leaders to discuss the impact that nuclear medicine is having on their field. It was...

Read more

Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022

Clinical, News,

Telix is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today...

Read more

Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide

Clinical, News,

Telix today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an immune checkpoint protein. The...

Read more